Omada valued at $1.3 billion as shares jump in Nasdaq debut > 자유게시판

Stock opens at $23 vs $19 IPO price



Company raises $150 million



IPO market sees resurgence with 142 US listings in 2025

*

Omada offers virtual care for chronic conditions like diabetes

(Adds analysts' comments in paragraphs 3, 5, 8, 9)

By Prakhar Srivastava

June 6 (Reuters) - Virtual healthcare provider Omada secured a valuation of $1.28 billion after its shares jumped 21% in their Nasdaq debut on Friday, reflecting renewed investor interest in public offerings after a prolonged slowdown.

The strong debut underscores a steady recovery in investor totoslot777 appetite for new listings at a time when U.S. President Donald Trump's tariff policies have rattled markets.

"The IPO market has seen a clear resurgence, with 142 U.S. IPOs launched in 2025 as of June 6, an 82% increase over the same period last year," AIP Asset Management CEO Jay Bala said.

A blowout debut of crypto company and stablecoin issuer Circle Internet on Thursday also fired up the IPO market.

"Fintech is positioned for a breakout year, with Circle's IPO setting the tone for a wave of high-quality offerings expected in the months ahead," Bala added.

Omada shares opened at $23 apiece, compared with its offer price of $19 per share. The California-based company raised $150 million by selling 7.9 million shares in the IPO.

Digital health platform Hinge Health, which debuted in May, has been trading 20.3% higher than its offer price, as of last close.

"The terrific after-market performance of Hinge certainly provided some tailwind for Omada," Edward Best, partner at Willkie Farr & Gallagher, said.

"These two IPOs are an indication that the market is receptive to technology-related healthcare IPOs."

Last month, retail trading platform eToro made a strong market debut, while digital banking startup Chime Financial is set to go public next week.

Founded in 2012, Omada offers virtual care programs for patients with chronic conditions such as prediabetes, diabetes and hypertension. Its prospectus describes the company's approach as a "between-visit care model" designed to complement the broader healthcare system.

(Reporting by Prakhar Srivastava in Bengaluru; Editing by Shilpi Majumdar and Shounak Dasgupta)